Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025
Rhea-AI Summary
Fennec Pharmaceuticals (NASDAQ: FENC), a commercial stage specialty pharmaceutical company, has scheduled its second quarter 2025 financial results announcement for Thursday, August 14, 2025. The results will be released before U.S. markets open, followed by a management conference call and webcast at 8:30 a.m. Eastern Time.
The company will host a live webcast accessible through their website, with a replay available for thirty days following the event. Participants are advised to connect at least 15 minutes early to allow for any necessary software downloads.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, FENC declined 0.96%, reflecting a mild negative market reaction. Argus tracked a peak move of +2.4% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $257M at that time.
Data tracked by StockTitan Argus on the day of publication.
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, August 14, 2025. Management will host a conference call and webcast that day to discuss the Company’s financial and business results.
Conference Call & Webcast Detail:
Date: Thursday, August 14, 2025
Time: 8:30 a.m. Eastern Time
Webcast Link: https://edge.media-server.com/mmc/p/de4jxxzj
Participant Link: https://register-conf.media-server.com/register/BI3e750b95d06c439ea560b46f60abda54
To access the live webcast link, log onto www.fennecpharma.com and proceed to the News & Events/Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to sparing cancer patients further hardship by protecting their ears against the profound threat of cisplatin-induced hearing loss, or ototoxicity. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSI.
In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand. PEDMARQSI is now commercially available in the U.K. and Germany.
PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection. Further, Fennec has patents providing protection for PEDMARK until 2039 in both the U.S. and internationally.
For more information, please visit www.fennecpharma.com and follow on LinkedIn.
For further information, please contact:
Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299
Corporate and Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com
FAQ
When will Fennec Pharmaceuticals (FENC) release Q2 2025 earnings?
What time is Fennec Pharmaceuticals' Q2 2025 earnings call?
How can investors access Fennec Pharmaceuticals' Q2 2025 earnings call?
Will there be a replay of Fennec Pharmaceuticals' Q2 2025 earnings call?
